Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy
Stock Information for LightPath Technologies Inc.
Loading
Please wait while we load your information from QuoteMedia.